公开(公告)号：US20070049525A1

公开(公告)日：2007-03-01

申请号：US11538561

申请日：2006-10-04

Applicant: Zeren Gao ,  Rolf Kuestner ,  Mark Appleby ,  Katherine Lewis ,  Patricia McKernan ,  Shannon Okada ,  David Taft ,  Joseph Kuijper ,  Stephen Jaspers ,  Steven Levin

Inventor： Zeren Gao ,  Rolf Kuestner ,  Mark Appleby ,  Katherine Lewis ,  Patricia McKernan ,  Shannon Okada ,  David Taft ,  Joseph Kuijper ,  Stephen Jaspers ,  Steven Levin

IPC: A61K38/17 ,  C07K14/715 ,  C07H21/04 ,  C12P21/06

CPC classification number: C07K14/7155 ,  A61K38/00 ,  A61K39/395 ,  A61K47/50 ,  A61K47/60 ,  C07K14/54 ,  C07K16/00

Abstract: The present invention relates ZcytoR21 antagonists, such as soluble receptors and anti-ZcytoR21 antibodies, that are useful in blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17C. IL-17C is a cytokine that is involved in inflammatory processes and human disease. ZcytoR21 is a receptor for IL-17C. The present invention includes soluble ZcytoR21, anti-ZcytoR21 antibodies and binding partners, as well as methods for antagonizing IL-17C using such soluble receptors, antibodies and binding partners.

Abstract translation: 本发明涉及可用于阻断，抑制，降低，拮抗或中和IL-17C活性的ZcytoR21拮抗剂，例如可溶性受体和抗ZcytoR21抗体。 IL-17C是涉及炎症过程和人类疾病的细胞因子。 ZcytoR21是IL-17C的受体。 本发明包括可溶性ZcytoR21，抗ZcytoR21抗体和结合配偶体，以及使用这种可溶性受体，抗体和结合配偶体拮抗IL-17C的方法。

公开(公告)号：US20050250126A1

公开(公告)日：2005-11-10

申请号：US11015546

申请日：2004-12-16

Applicant: Zeren Gao ,  Paul Sheppard ,  Brian Fox ,  James Holloway ,  Stephen Jaspers ,  Mark Appleby

Inventor： Zeren Gao ,  Paul Sheppard ,  Brian Fox ,  James Holloway ,  Stephen Jaspers ,  Mark Appleby

IPC: C07H21/04 ,  C07K14/525 ,  C07K14/705 ,  C07K16/24 ,  C07K16/28 ,  C12P21/02 ,  C12P21/06 ,  C12Q1/68

CPC classification number: C07K14/525 ,  C07K16/2875 ,  C07K2317/34

Abstract: Novel tumor necrosis factor ligand polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed. The polypeptides may be used within methods relating to immune response, and may also be used in the development of immuno-regulatory therapeutics. Also provided are antibodies, binding proteins, agonists and antagonists of the ligand polypeptides.

Abstract translation: 公开了新型肿瘤坏死因子配体多肽，编码多肽的多核苷酸，以及相关的组合物和方法。 多肽可用于与免疫应答相关的方法中，并且也可用于开发免疫调节治疗。 还提供了配体多肽的抗体，结合蛋白，激动剂和拮抗剂。

公开(公告)号：US20080215665A1

公开(公告)日：2008-09-04

申请号：US11915597

申请日：2006-05-12

Applicant: Richard Mark Appleby ,  Bharat Veer Bedi ,  Martin Gale ,  Lucas William Partridge

Inventor： Richard Mark Appleby ,  Bharat Veer Bedi ,  Martin Gale ,  Lucas William Partridge

IPC: G06F15/16

CPC classification number: H04L67/125 ,  H04L43/00 ,  H04L67/04

Abstract: A method for generating an update status alert at a receiving device, the receiving device operating in a network of participating devices, each participating device broadcasting status information about a monitored entity associated with a respective participating device, the method comprising the steps of: receiving broadcast status information from each of the participating devices; aggregating the received status information to derive a consensus of the status information received from each of the participating devices; comparing the derived consensus with the status of the monitored entity of the receiving device; detecting a difference between the derived consensus and the status of the monitored entity; and in dependence of a difference being determined, generating an update status alert at the receiving device.

Abstract translation: 一种用于在接收设备处生成更新状态警报的方法，所述接收设备在参与设备的网络中操作，每个参与设备广播关于与相应参与设备相关联的被监控实体的状态信息，所述方法包括以下步骤：接收广播 来自每个参与设备的状态信息; 聚合所接收的状态信息以导出从每个参与设备接收到的状态信息的一致性; 将导出的一致性与接收设备的被监控实体的状态进行比较; 检测得出的共识与受监控实体的状态之间的差异; 并且根据确定的差异，在接收设备处生成更新状态警报。

公开(公告)号：US20070049524A1

公开(公告)日：2007-03-01

申请号：US11538549

申请日：2006-10-04

Applicant: Zeren Gao ,  Rolf Kuestner ,  Mark Appleby ,  Katherine Lewis ,  Patricia McKernan ,  Shannon Okada ,  David Taft ,  Joseph Kuijper ,  Stephen Jaspers ,  Steven Levin

Inventor： Zeren Gao ,  Rolf Kuestner ,  Mark Appleby ,  Katherine Lewis ,  Patricia McKernan ,  Shannon Okada ,  David Taft ,  Joseph Kuijper ,  Stephen Jaspers ,  Steven Levin

IPC: A61K38/17

CPC classification number: C07K14/7155 ,  A61K38/00 ,  A61K39/395 ,  A61K47/50 ,  A61K47/60 ,  C07K14/54 ,  C07K16/00

Abstract: The present invention relates ZcytoR21 antagonists, such as soluble receptors and anti-ZcytoR21 antibodies, that are useful in blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17C. IL-17C is a cytokine that is involved in inflammatory processes and human disease. ZcytoR21 is a receptor for IL-17C. The present invention includes soluble ZcytoR21, anti-ZcytoR21 antibodies and binding partners, as well as methods for antagonizing IL-17C using such soluble receptors, antibodies and binding partners.

公开(公告)号：US08219666B2

公开(公告)日：2012-07-10

申请号：US11915597

申请日：2006-05-12

Applicant: Richard Mark Appleby ,  Bharat Veer Bedi ,  Martin Gale ,  Lucas William Partridge

Inventor： Richard Mark Appleby ,  Bharat Veer Bedi ,  Martin Gale ,  Lucas William Partridge

IPC: G06F15/16

CPC classification number: H04L67/125 ,  H04L43/00 ,  H04L67/04

Abstract: A method for generating an update status alert at a receiving device, the receiving device operating in a network of participating devices, each participating device broadcasting status information about a monitored entity associated with a respective participating device, the method comprising the steps of: receiving broadcast status information from each of the participating devices; aggregating the received status information to derive a consensus of the status information received from each of the participating devices; comparing the derived consensus with the status of the monitored entity of the receiving device; detecting a difference between the derived consensus and the status of the monitored entity; and in dependence of a difference being determined, generating an update status alert at the receiving device.

Abstract translation: 一种用于在接收设备处生成更新状态警报的方法，所述接收设备在参与设备的网络中操作，每个参与设备广播关于与相应参与设备相关联的被监控实体的状态信息，所述方法包括以下步骤：接收广播 来自每个参与设备的状态信息; 聚合所接收的状态信息以导出从每个参与设备接收到的状态信息的一致性; 将导出的一致性与接收设备的被监控实体的状态进行比较; 检测得出的共识与受监控实体的状态之间的差异; 并且根据确定的差异，在接收设备处生成更新状态警报。

公开(公告)号：US20060142192A1

公开(公告)日：2006-06-29

申请号：US11253200

申请日：2005-10-18

Applicant: Zeren Gao ,  Rolf Kuestner ,  Mark Appleby ,  Katherine Lewis ,  Patricia McKernan ,  Shannon Okada ,  David Taft ,  Joseph Kuijper ,  Stephen Jaspers ,  Steven Levin

Inventor： Zeren Gao ,  Rolf Kuestner ,  Mark Appleby ,  Katherine Lewis ,  Patricia McKernan ,  Shannon Okada ,  David Taft ,  Joseph Kuijper ,  Stephen Jaspers ,  Steven Levin

IPC: A61K38/17 ,  C07K14/715

CPC classification number: C07K14/7155 ,  A61K38/00 ,  A61K39/395 ,  A61K47/50 ,  A61K47/60 ,  C07K14/54 ,  C07K16/00

Abstract: The present invention relates ZcytoR21 antagonists, such as soluble receptors and anti-ZcytoR21 antibodies, that are useful in blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17C. IL-17C is a cytokine that is involved in inflammatory processes and human disease. ZcytoR21 is a receptor for IL-17C. The present invention includes soluble ZcytoR21, anti-ZcytoR21 antibodies and binding partners, as well as methods for antagonizing IL-17C using such soluble receptors, antibodies and binding partners.

Abstract translation: 本发明涉及可用于阻断，抑制，降低，拮抗或中和IL-17C活性的ZcytoR21拮抗剂，例如可溶性受体和抗ZcytoR21抗体。 IL-17C是涉及炎症过程和人类疾病的细胞因子。 ZcytoR21是IL-17C的受体。 本发明包括可溶性ZcytoR21，抗ZcytoR21抗体和结合配偶体，以及使用这种可溶性受体，抗体和结合配偶体拮抗IL-17C的方法。

公开(公告)号：US20070129302A1

公开(公告)日：2007-06-07

申请号：US11550609

申请日：2006-10-18

Applicant: Zeren Gao ,  Rolf Kuestner ,  Mark Appleby ,  Katherine Lewis ,  Patricia McKernan ,  Shannon Okada ,  David Taft ,  Joseph Kuijper ,  Stephen Jaspers ,  Steven Levin

Inventor： Zeren Gao ,  Rolf Kuestner ,  Mark Appleby ,  Katherine Lewis ,  Patricia McKernan ,  Shannon Okada ,  David Taft ,  Joseph Kuijper ,  Stephen Jaspers ,  Steven Levin

IPC: A61K38/17 ,  C07K14/715 ,  C07H21/04 ,  C12P21/06

CPC classification number: C07K14/7155 ,  A61K38/00 ,  C07K2319/20 ,  C07K2319/21 ,  C07K2319/30

Abstract: The present invention relates IL-17RE antagonists, such as soluble receptors and anti-IL-17RE antibodies, that are useful in blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17C. IL-17C is a cytokine that is involved in inflammatory processes and human disease. IL-17RE is a receptor for IL-17C. The present invention includes soluble IL-17RE, anti-IL-17RE antibodies and binding partners, as well as methods for antagonizing IL-17C using such soluble receptors, antibodies and binding partners.

Abstract translation: 本发明涉及可用于阻断，抑制，降低，拮抗或中和IL-17C活性的IL-17RE拮抗剂，例如可溶性受体和抗IL-17RE抗体。 IL-17C是涉及炎症过程和人类疾病的细胞因子。 IL-17RE是IL-17C的受体。 本发明包括可溶性IL-17RE，抗IL-17RE抗体和结合配偶体，以及使用这种可溶性受体，抗体和结合配偶体拮抗IL-17C的方法。

公开(公告)号：US20060083740A1

公开(公告)日：2006-04-20

申请号：US10496284

申请日：2002-11-21

Applicant: Fred Ramsdell ,  Sean Proll ,  Karen Staehling-Hampton ,  Mark Appleby ,  Leon Garcia-Martinez

Inventor： Fred Ramsdell ,  Sean Proll ,  Karen Staehling-Hampton ,  Mark Appleby ,  Leon Garcia-Martinez

IPC: A61K39/395 ,  C07K16/24

CPC classification number: C07K16/2803 ,  A61K38/00 ,  A61K2039/505 ,  C07K14/70503 ,  C07K2317/56 ,  C07K2317/565 ,  Y02A50/397 ,  Y02A50/41 ,  Y02A50/423 ,  Y02A50/484

Abstract: The invention provides methods for modulating cytokine levels, GM-CSF levels and the immune system using CD83 nucleic acids, CD83 polypeptides, anti-CD83 antibodies and factors that influence CD83 activity or expression. The invention also provides mice having a mutant CD83 gene and mice having a transgenic CD83 gene, which are useful for defining the role of CD83 in the immune system and for identifying compounds that can modulate CD83 and the immune system.

Abstract translation: 本发明提供了使用CD83核酸，CD83多肽，抗CD83抗体和影响CD83活性或表达的因子调节细胞因子水平，GM-CSF水平和免疫系统的方法。 本发明还提供具有突变CD83基因的小鼠和具有转基因CD83基因的小鼠，其可用于定义CD83在免疫系统中的作用并鉴定可调节CD83和免疫系统的化合物。